RAB11B, member RAS oncogene familyGenealiases: H-YPT3 · NDAGSCW
Q-omics provides the consensus-scored RAB11B profile across patient tissues and cancer cell-line models. RAB11B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RAB11B is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, RAB11B protein abundance shows 20,126 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, THCA, and LSCC as cancer lineages where RAB11B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB11B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB11B survival associations across molecular data types. RAB11B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB11B RNA expression–survival associations across cancer types. High RAB11B expression shows unfavorable associations in ACC and READ, but favorable associations in HNSC, SCLC, BLCA and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for RAB11B RNA expression.
This table summarizes RAB11B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB11B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB11B shows lower tumor expression in THCA, KIRC, LUAD and KICH and higher tumor expression in LIHC and HNSC. The THCA box plot shows higher RAB11B RNA expression in normal versus tumor tissue (log2 FC = −0.530, t-test p < 0.001).
This table shows molecular features associated with RAB11B in patient tissues and cancer cell lines. In patient samples, RAB11B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB11B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
